Semaglutide News and Research

Latest Semaglutide News and Research

Diabetes drugs linked to higher risk of rare optic nerve damage

...

14 Aug 2025

Updated multidisciplinary European guidelines redefine MASLD diagnosis and treatment

The 2024 European clinical practice guidelines introduce a pivotal terminology shift, replacing NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH with MASH (metabolic dysfunction-associated steatohepatitis).

7 Aug 2025

RAND study highlights patterns of GLP-1 medication use and side effects

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report.

6 Aug 2025

Weight loss with ozempic may weaken muscles even when size remains stable

As use of the popular anti-diabetic and weight-loss drug Ozempic skyrockets, so have concerns about the medication's side effects.

5 Aug 2025

HIV trial points to semaglutide as a new anti-aging contender

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by multiple DNA methylation clocks in a randomized controlled trial. These exploratory findings suggest GLP-1 receptor agonists could impact biological aging but require further validation in broader populations.

4 Aug 2025

Metformin lowers blood sugar by acting on brain pathways

Although metformin has been the go-to medication to manage type 2 diabetes for more than 60 years, researchers still do not have a complete picture of how it works.

31 Jul 2025

Gut microbial metabolites restore hormone-producing cells in obesity

New research from scientists at the Marshall University Joan C. Edwards School of Medicine reveals that certain gut microbial byproducts may hold promise as a novel therapy for obesity-associated metabolic complications by restoring critical hormone-producing cells in the intestine.

29 Jul 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

Extreme childhood obesity drives liver and diabetes risks

Extreme obesity in US youth has risen significantly, linked to higher rates of diabetes and liver complications, necessitating immediate public health action.

22 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

Muscle loss from GLP-1 drugs could undermine long-term health

Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in heart and lung function essential for long-term good health, University of Virginia experts warn in a new paper.

21 Jul 2025

Retrospective analyses indicate Ozempic’s protective effects against stroke fatality

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether.

18 Jul 2025

Extracellular vesicle RNA reveals clues about obesity and metabolic disease

Our study examines how RNA in extracellular vesicles (EVs) can provide insights into metabolic phenotypes related to obesity. By using functional genomics approaches, we found a high representation of genes and regulatory elements previously associated with obesity and type 2 diabetes represented by the RNA cargo within these EVs.

15 Jul 2025

Effective weight loss achieved even with inconsistent GLP-1 access

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, according to a study being presented by a private weight-loss company Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

15 Jul 2025

Weight loss drugs can boost testosterone in men with obesity or diabetes

Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

14 Jul 2025

New guideline recommends proper preconception care for women with diabetes

A joint guideline released today from the Endocrine Society and the European Society of Endocrinology (ESE) recommends women with diabetes receive proper preconception care and access to emerging diabetes technology and therapeutics to manage their blood sugar before, during and after pregnancy.

13 Jul 2025

Higher protein intake may help prevent muscle loss in semaglutide users

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Combining tirzepatide and hormone therapy boosts weight loss in postmenopausal women

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025